Mitsubishi UFJ Trust & Banking Corp Has $21.37 Million Holdings in BioNTech SE (NASDAQ:BNTX)

Mitsubishi UFJ Trust & Banking Corp trimmed its holdings in BioNTech SE (NASDAQ:BNTX) by 1.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 187,516 shares of the company’s stock after selling 3,026 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.08% of BioNTech worth $21,367,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. FMR LLC raised its holdings in BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after acquiring an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC bought a new position in shares of BioNTech in the third quarter worth $59,485,000. Braidwell LP acquired a new position in BioNTech in the third quarter valued at about $29,425,000. abrdn plc lifted its position in BioNTech by 70.7% during the fourth quarter. abrdn plc now owns 385,668 shares of the company’s stock worth $43,947,000 after purchasing an additional 159,676 shares during the period. Finally, Redmile Group LLC acquired a new stake in BioNTech during the third quarter worth about $18,345,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Price Performance

BNTX stock opened at $95.40 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a market capitalization of $22.89 billion, a P/E ratio of -45.43 and a beta of 0.30. The company has a fifty day moving average price of $111.75 and a 200-day moving average price of $113.59.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.90 EPS. As a group, equities analysts expect that BioNTech SE will post -3.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on BNTX shares. Wells Fargo & Company assumed coverage on shares of BioNTech in a research report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price for the company. Citigroup assumed coverage on shares of BioNTech in a research report on Thursday, March 13th. They set a “buy” rating and a $145.00 price objective for the company. BMO Capital Markets raised their target price on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Truist Financial began coverage on BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 price target for the company. Finally, Morgan Stanley reduced their price objective on BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $143.73.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.